Four experts will provide an update on lipid-lowering drugs during a two-hour virtual presentation at the Scientific Sessions. The session’s panelists include Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC; Jennifer G. Robinson, MD, MPH; and John R. Guyton, MD.

Detailed findings from the VERTIS-CV trial looking at the safety and efficacy of ertugliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, will be presented Tuesday, June 16, by a panel of trial investigators. Christopher P. Cannon, MD, a member of the VERTIS-CV trial Scientific Advisory Committee, will present cardiovascular and renal outcomes from the trial.

A panel of investigators, including Beena Akolkar, PhD, will present recent findings from the ongoing TEDDY Study during the Scientific Sessions. TEDDY is a multi-center study funded by the NIDDK designed to investigate the etiology of type 1 diabetes and identify environmental triggers of the disease.

Ongoing advances in the accuracy and affordability of continuous glucose monitoring technologies have led to a growing emphasis on time-in-range as a primary metric in pediatric diabetes. A panel of experts, including Daniel J. DeSalvo, MD, will review the growing evidence supporting time-in-range and discuss recommendations for incorporating the metric into clinical practice during the…

During a Friday afternoon symposium at the Scientific Sessions, a panel of experts will discuss the latest recommendations and research findings regarding treatment options for patients with common diabetes comorbidities. Panelists include George Bakris, MD, Silvio E. Inzucchi, MD, and Jesse Dawson, MD, BSc (Hons), FRCP, FESO.

Results from the PIONEER 6 trial suggest that oral semaglutide is safe for patients with type 2 diabetes at high cardiovascular (CV) risk. PIONEER researchers, including Mansoor Husain, MD, and John B. Buse, MD, PhD, reported that oral semaglutide, the first GLP-1 receptor agonist for oral administration, reduced CV death and all-cause mortality by nearly…

The results of two major outcome trials — CREDENCE and CARMELINA — targeting patients with type 2 diabetes and chronic kidney disease were presented on Tuesday, June 11, the final day of the 79th Scientific Sessions in San Francisco, CA. Meg Jardine, MD, PhD, discusses CREDENCE results and Darren K. McGuire, MD, MHSc, reports on…

In a head-to-head comparison of linagliptin, a DPP-4 inhibitor, and glimepiride, a sulfonylurea, researchers found no difference in risk for cardiovascular mortality or overall mortality in patients with type 2 diabetes, according to Julio Rosenstock, MD.